{"id":"ticlopidine","rwe":[],"tags":[],"safety":{"commonSideEffects":[{"effect":"Any Events","drugRate":"60.0%","severity":"serious"},{"effect":"Diarrhea","drugRate":"12.5%","severity":"common"},{"effect":"Nausea","drugRate":"7.0%","severity":"common"},{"effect":"Dyspepsia","drugRate":"7.0%","severity":"common"},{"effect":"Rash","drugRate":"5.1%","severity":"common"},{"effect":"GI Pain","drugRate":"3.7%","severity":"mild"},{"effect":"Neutropenia","drugRate":"2.4%","severity":"mild"},{"effect":"Purpura","drugRate":"2.2%","severity":"mild"},{"effect":"Vomiting","drugRate":"1.9%","severity":"mild"},{"effect":"Flatulence","drugRate":"1.5%","severity":"mild"},{"effect":"Pruritus","drugRate":"1.3%","severity":"mild"},{"effect":"Dizziness","drugRate":"1.1%","severity":"mild"},{"effect":"Anorexia","drugRate":"1.0%","severity":"mild"},{"effect":"Abnormal Liver Function Test","drugRate":"1.0%","severity":"mild"},{"effect":"GI fullness","drugRate":"reported","severity":"unknown"},{"effect":"Urticaria","drugRate":"reported","severity":"unknown"},{"effect":"Headache","drugRate":"reported","severity":"unknown"},{"effect":"Asthenia","drugRate":"reported","severity":"unknown"},{"effect":"Pain","drugRate":"reported","severity":"unknown"},{"effect":"Epistaxis","drugRate":"reported","severity":"unknown"},{"effect":"Tinnitus","drugRate":"reported","severity":"unknown"},{"effect":"Hemolytic anemia with reticulocytosis","drugRate":"reported","severity":"unknown"},{"effect":"Immune thrombocytopenia","drugRate":"reported","severity":"unknown"},{"effect":"Hepatitis","drugRate":"reported","severity":"unknown"},{"effect":"Hepatocellular jaundice","drugRate":"reported","severity":"unknown"},{"effect":"Cholestatic jaundice","drugRate":"reported","severity":"unknown"},{"effect":"Hepatic necrosis","drugRate":"reported","severity":"unknown"},{"effect":"Hepatic failure","drugRate":"reported","severity":"unknown"},{"effect":"Peptic ulcer","drugRate":"reported","severity":"unknown"},{"effect":"Renal failure","drugRate":"reported","severity":"unknown"}],"contraindications":["Acute nephropathy","Arterial aneurysm","Ascorbic acid deficiency","Bleeding","Blood coagulation disorder","Cerebral hemorrhage","Congenital hypoplastic anemia","Gastrointestinal hemorrhage","Gastrointestinal ulcer","Hyperlipidemia","Leukemia, disease","Lumbar puncture","Neutropenic disorder","Obstruction of bile duct","Procedure on central nervous system","Surgical procedure","Thrombocytopenic disorder","Thrombotic thrombocytopenic purpura"]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T17:01:25.626690","allNames":"ticlid","offLabel":[],"timeline":[],"_dailymed":{"setId":"77d619f8-05a3-408a-a6f8-1511694b6a24","title":"TICLOPIDINE HYDROCHLORIDE TABLET, FILM COATED [CARILION MATERIALS MANAGEMENT]"},"ecosystem":[],"mechanism":{"target":"Cytochrome P450 2B6, Bile salt export pump, Cytochrome P450 2A6","modality":"Small Molecule"},"_scrapedAt":"2026-03-28T00:37:08.001Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"indications":{"approved":[{"name":"Cerebrovascular Occlusion","diseaseId":"cerebrovascular-occlusion","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Percutaneous coronary intervention","diseaseId":"percutaneous-coronary-intervention","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of Cerebral Thrombosis","diseaseId":"prevention-of-cerebral-thrombosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Subacute Stent Thrombosis Prevention","diseaseId":"subacute-stent-thrombosis-prevention","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["sideEffects","pubmed(2587)","generics(8)","patents(0)","modality→Small Molecule"],"labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[{"nctId":"NCT06757764","phase":"PHASE4","title":"The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-07-10","conditions":"Cerebral Infarction, Stenosis Artery","enrollment":2340},{"nctId":"NCT06650488","phase":"PHASE4","title":"Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia","status":"RECRUITING","sponsor":"Todd C. Lee MD MPH FIDSA","startDate":"2026-01-15","conditions":"Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bloodstream Infection","enrollment":300},{"nctId":"NCT05047172","phase":"PHASE3","title":"Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2022-08-02","conditions":"Intracranial Arteriosclerosis, Stroke","enrollment":1683},{"nctId":"NCT05681702","phase":"PHASE4","title":"Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI","status":"RECRUITING","sponsor":"University of Florida","startDate":"2023-02-15","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT07454707","phase":"PHASE3","title":"Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial","status":"NOT_YET_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2026-04","conditions":"Stroke, Ischemic","enrollment":1204},{"nctId":"NCT06037889","phase":"PHASE3","title":"Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2023-11-09","conditions":"Branch Atheromatous Disease","enrollment":516},{"nctId":"NCT04809818","phase":"PHASE1","title":"A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects","status":"COMPLETED","sponsor":"Lumosa Therapeutics Co., Ltd.","startDate":"2021-03-21","conditions":"Acute Ischemic Stroke","enrollment":65},{"nctId":"NCT06588595","phase":"PHASE4","title":"The Switching Antiplatelet-9 (SWAP-9) Study","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-11-01","conditions":"Coronary Arterial Disease (CAD)","enrollment":90},{"nctId":"NCT01652209","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.","status":"COMPLETED","sponsor":"Pharmicell Co., Ltd.","startDate":"2013-09-01","conditions":"Acute Myocardial Infarction","enrollment":90},{"nctId":"NCT04014803","phase":"PHASE4","title":"Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2020-01-13","conditions":"Coronary Artery Disease","enrollment":3500},{"nctId":"NCT07384702","phase":"PHASE2","title":"Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia","status":"NOT_YET_RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2026-06","conditions":"Bacteremia Due to Staphylococcus Aureus","enrollment":230},{"nctId":"NCT06228456","phase":"PHASE4","title":"Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"University of Florida","startDate":"2024-04-01","conditions":"Coronary Artery Disease","enrollment":50},{"nctId":"NCT07390513","phase":"","title":"Electrophysiological Outcomes After Transcatheter Aortic Valve Replacement","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2022-01-01","conditions":"Aortic Valve Stenosis, Arrhythmia","enrollment":1000},{"nctId":"NCT07379190","phase":"PHASE3","title":"HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)","status":"NOT_YET_RECRUITING","sponsor":"Weifang Medical University","startDate":"2026-02-01","conditions":"Stroke, Acute, Stroke, Ischemic, Cerebral Infarction","enrollment":458},{"nctId":"NCT04654052","phase":"PHASE4","title":"VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación EPIC","startDate":"2021-07-02","conditions":"Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease","enrollment":634},{"nctId":"NCT07358416","phase":"","title":"Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2025-05-01","conditions":"Thrombosis, Bleeding, Cerebral Hypoxia During and/or Resulting From A Procedure","enrollment":500},{"nctId":"NCT04822363","phase":"EARLY_PHASE1","title":"The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2021-08-20","conditions":"Platelet Activation Testing Before/After Anti-platelet Therapy, Healthy","enrollment":112},{"nctId":"NCT05577988","phase":"PHASE3","title":"Assessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-06-18","conditions":"MYOCARDIAL INFARCTION","enrollment":2468},{"nctId":"NCT07076082","phase":"PHASE4","title":"Vascular Trial Associated Registry Pilot","status":"RECRUITING","sponsor":"Corewell Health West","startDate":"2025-10-15","conditions":"Peripheral Arterial Disease","enrollment":350},{"nctId":"NCT03783351","phase":"NA","title":"Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2019-05-27","conditions":"Angina, Stable, Acute Coronary Syndrome, Drug-Eluting Stents","enrollment":4009},{"nctId":"NCT05257824","phase":"PHASE4","title":"Optimal Duration of Dual Antiplatelet Therapy After Stent-assisted Coiling","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2022-06-23","conditions":"Aneurysm Cerebral, Endovascular Procedures","enrollment":528},{"nctId":"NCT03463317","phase":"PHASE4","title":"Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-02-28","conditions":"Atrial Fibrillation","enrollment":912},{"nctId":"NCT06238115","phase":"PHASE2, PHASE3","title":"Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2024-03-04","conditions":"Unruptured Intracranial Aneurysm, Flow Diverter, Stent-assisted Coiling","enrollment":192},{"nctId":"NCT07275749","phase":"PHASE3","title":"Acetyl-leucine in Post-stroke Ataxia","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2025-12-01","conditions":"Ischemic Stroke","enrollment":200},{"nctId":"NCT05646394","phase":"","title":"Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS","status":"RECRUITING","sponsor":"McMaster University","startDate":"2022-07-01","conditions":"Antiphospholipid Syndrome, Arterial Thrombosis","enrollment":150},{"nctId":"NCT02505399","phase":"PHASE4","title":"TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2015-11","conditions":"Atherosclerosis","enrollment":180},{"nctId":"NCT07265466","phase":"PHASE1","title":"to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban","status":"RECRUITING","sponsor":"Onconic Therapeutics Inc.","startDate":"2025-11-17","conditions":"Drug Drug Interaction (DDI)","enrollment":96},{"nctId":"NCT07012629","phase":"PHASE3","title":"A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-11-26","conditions":"Covert Brain Infarction","enrollment":1652},{"nctId":"NCT05752916","phase":"PHASE4","title":"Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-06-02","conditions":"Acute Ischemic Stroke","enrollment":570},{"nctId":"NCT04624854","phase":"PHASE4","title":"Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)","status":"COMPLETED","sponsor":"Harbin Medical University","startDate":"2020-10-28","conditions":"Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome","enrollment":8250},{"nctId":"NCT05445895","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2022-12-16","conditions":"Ischemic Stroke","enrollment":483},{"nctId":"NCT06714526","phase":"NA","title":"Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2025-10-07","conditions":"Intracranial Atherosclerosis","enrollment":100},{"nctId":"NCT07237308","phase":"PHASE4","title":"BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-12","conditions":"Stroke, Ischemic, Atrial Fibrillation","enrollment":586},{"nctId":"NCT03378934","phase":"PHASE4","title":"Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2018-09-26","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention","enrollment":64},{"nctId":"NCT06336174","phase":"","title":"Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study","status":"RECRUITING","sponsor":"Anhui Medical University","startDate":"2022-11-01","conditions":"Intracranial Atherosclerosis, Cognitive Impairment, Cerebrovascular Event","enrollment":100},{"nctId":"NCT07025148","phase":"PHASE4","title":"Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)","status":"RECRUITING","sponsor":"University of Florida","startDate":"2025-10-01","conditions":"Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)","enrollment":40},{"nctId":"NCT07195812","phase":"PHASE4","title":"Rivaroxaban for Slow Coronary Flow After PCI in STEMI","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-10","conditions":"ST Elevation Myocardial Infarction, No-Reflow Phenomenon","enrollment":60},{"nctId":"NCT07180472","phase":"PHASE4","title":"Prevention of Stroke Recurrence and Disease Progression in Cerebral Small Vessel Disease With Cilostazol","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Chengdu Medical College","startDate":"2025-09-20","conditions":"Cerebral Small Vessel Disease","enrollment":632},{"nctId":"NCT03289520","phase":"PHASE3","title":"Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2003-01-07","conditions":"Kidney Failure, Hemodialysis Fistula Thrombosis","enrollment":877},{"nctId":"NCT07169513","phase":"NA","title":"Mechanistic Study of Anti-Platelet Therapy in Atherosclerosis","status":"NOT_YET_RECRUITING","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2025-10-01","conditions":"Peripheral Arterial Disease, Silent Atherosclerosis","enrollment":60},{"nctId":"NCT06638151","phase":"PHASE2","title":"Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPrime)","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2025-09-02","conditions":"Acute Ischemic Stroke","enrollment":200},{"nctId":"NCT07067775","phase":"PHASE1","title":"Pharmacokinetic/Pharmacodynamic Study of Vicagrel Capsules and Clopidogrel Tablets in Healthy CYP2C19 Normal Metabolizers","status":"COMPLETED","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2025-08-05","conditions":"Acute Coronary Syndrome","enrollment":18},{"nctId":"NCT06591338","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-09-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT06360120","phase":"PHASE3","title":"Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-04-10","conditions":"Ischemic Stroke","enrollment":600},{"nctId":"NCT03431142","phase":"PHASE4","title":"Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients Trial","status":"COMPLETED","sponsor":"Shenyang Northern Hospital","startDate":"2018-02-12","conditions":"Prolonged DAPT in ACS Patients With Hisk of Both Ischemic and Hemorrhage","enrollment":7758},{"nctId":"NCT07040787","phase":"PHASE1","title":"Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects","status":"COMPLETED","sponsor":"Chengdu Suncadia Medicine Co., Ltd.","startDate":"2025-07-08","conditions":"Complement Mediated Glomerular Diseases, Hemolytic Anemia","enrollment":36},{"nctId":"NCT07095790","phase":"PHASE4","title":"Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2025-08-30","conditions":"Mild Stroke","enrollment":580},{"nctId":"NCT04483583","phase":"PHASE4","title":"Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI","status":"COMPLETED","sponsor":"University of Florida","startDate":"2020-12-08","conditions":"Coronary Artery Disease","enrollment":81},{"nctId":"NCT06414499","phase":"PHASE3","title":"Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅳ","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-07-09","conditions":"Minor Ischemic Stroke","enrollment":1386},{"nctId":"NCT07080684","phase":"PHASE4","title":"Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease","status":"NOT_YET_RECRUITING","sponsor":"University of Messina","startDate":"2025-12-01","conditions":"Chronic Coronary Syndrome","enrollment":1000},{"nctId":"NCT06318481","phase":"PHASE3","title":"TADCLOT- a Double Blind Randomized Controlled Trial","status":"COMPLETED","sponsor":"National Institute of Cardiovascular Diseases, Pakistan","startDate":"2024-02-19","conditions":"Stent Thrombosis, Myocardial Infarction, Acute","enrollment":2200},{"nctId":"NCT03430661","phase":"PHASE1","title":"A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects","status":"COMPLETED","sponsor":"Viatris Innovation GmbH","startDate":"2018-01-24","conditions":"Healthy","enrollment":77},{"nctId":"NCT05643651","phase":"PHASE4","title":"Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-06-01","conditions":"Kawasaki Disease, Coronary Artery Aneurysm","enrollment":100},{"nctId":"NCT03357874","phase":"PHASE3","title":"TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2018-10-28","conditions":"Acute Coronary Syndrome","enrollment":259},{"nctId":"NCT01777503","phase":"PHASE4","title":"The Elderly ACS II Trial","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2012-11","conditions":"Acute Coronary Syndrome, Coronary Arteriosclerosis, Myocardial Ischemia","enrollment":1457},{"nctId":"NCT03496506","phase":"PHASE1","title":"A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2018-03-05","conditions":"Healthy Subjects","enrollment":22},{"nctId":"NCT06983795","phase":"","title":"Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-07","conditions":"Ischemic Stroke, Patent Foramen Ovale","enrollment":1000},{"nctId":"NCT06509893","phase":"PHASE4","title":"Ticagrelore Alone Post PCI","status":"RECRUITING","sponsor":"Shiraz University of Medical Sciences","startDate":"2024-08-01","conditions":"Coronary Artery Disease","enrollment":5400},{"nctId":"NCT06763744","phase":"PHASE4","title":"Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-06-01","conditions":"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), High Bleeding Risk","enrollment":3000},{"nctId":"NCT04219774","phase":"PHASE2","title":"NeuroCognition After Carotid Recanalization","status":"COMPLETED","sponsor":"Duke University","startDate":"2020-05-01","conditions":"Cognition Disorder, Stroke, Occlusion Carotid","enrollment":25},{"nctId":"NCT05566301","phase":"","title":"Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)","status":"RECRUITING","sponsor":"IRCCS Policlinico S. Donato","startDate":"2021-09-02","conditions":"Clopidogrel, Poor Metabolism of, Carotid Stenosis","enrollment":1140},{"nctId":"NCT05122455","phase":"PHASE2, PHASE3","title":"Effects of Edoxaban on Platelet Aggregation","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2021-09-14","conditions":"SCAD, AMI","enrollment":61},{"nctId":"NCT03298906","phase":"PHASE1","title":"A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-09-26","conditions":"Healthy","enrollment":16},{"nctId":"NCT05567562","phase":"PHASE2","title":"Anti-Platelets in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2024-03-27","conditions":"COPD, Emphysema, Emphysema or COPD","enrollment":19},{"nctId":"NCT06821191","phase":"PHASE4","title":"Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study","status":"RECRUITING","sponsor":"University of Florida","startDate":"2025-03-10","conditions":"Coronary Artery Disease","enrollment":78},{"nctId":"NCT06449469","phase":"NA","title":"The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-05-01","conditions":"Aortic Valve Stenosis, Cardiovascular Diseases, Heart Diseases","enrollment":352},{"nctId":"NCT04770012","phase":"PHASE3","title":"AERIAL Trial: Antiplatelet Therapy in Heart Transplantation","status":"RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2021-06-28","conditions":"Cardiac Allograft Vasculopathy, Heart Transplant","enrollment":135},{"nctId":"NCT04484259","phase":"PHASE4","title":"Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Florida","startDate":"2021-03-31","conditions":"Diabetes Mellitus, Type 2, Coronary Artery Disease","enrollment":105},{"nctId":"NCT06715007","phase":"","title":"Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-12-20","conditions":"Stroke, Ischemic, Small Vessel Cerebrovascular Disease, White Matter Hyperintensity","enrollment":300},{"nctId":"NCT04824911","phase":"PHASE2","title":"Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-03-23","conditions":"Acute Stroke, Dual Antiplatelet Therapy, Statin","enrollment":376},{"nctId":"NCT06281041","phase":"","title":"Nationwide Cohort Study of Antiplatelet Agents as Primary Prevention","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2013-01-01","conditions":"Coronary Artery Disease, Coronary Artery Stenosis","enrollment":4657},{"nctId":"NCT06872541","phase":"PHASE2, PHASE3","title":"Evaluation of Platelet Aggregability in Patients with Non-small Cell Lung Carcinomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo","startDate":"2025-01-20","conditions":"Assessment of Platelet Aggregability in Patients Patients with Non-small Cell Lung Carcinoma","enrollment":100},{"nctId":"NCT06873321","phase":"PHASE4","title":"VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization","status":"RECRUITING","sponsor":"Science Valley Research Institute","startDate":"2024-02-24","conditions":"Peripheral Arterial Disease, Venous Thormboembolism, Cardiovascular Diseases","enrollment":100},{"nctId":"NCT04946734","phase":"PHASE3","title":"Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2021-08-12","conditions":"PFO - Patent Foramen Ovale, Migraine","enrollment":440},{"nctId":"NCT06601127","phase":"PHASE2","title":"Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).","status":"RECRUITING","sponsor":"Tianjin Institute of Pharmaceutical Research Co., Ltd","startDate":"2025-02-21","conditions":"Ischemic Stroke","enrollment":600},{"nctId":"NCT05353140","phase":"NA","title":"LAAO Versus NOAC in Patients with AF and PCI","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2022-09-01","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":1386},{"nctId":"NCT06807788","phase":"","title":"Evaluation of Platelet Aggregability in Patients with Takayasu's Arteritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jose Carlos Nicolau","startDate":"2024-10-14","conditions":"Takayasu Arteritis (TAK), Vasculitis, Systemic","enrollment":100},{"nctId":"NCT02398656","phase":"PHASE3","title":"A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2015-04-01","conditions":"Stroke, Acute","enrollment":1274},{"nctId":"NCT03245489","phase":"PHASE1","title":"Anti-platelet + Pembro for H&N Tumors","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2018-03-06","conditions":"Head and Neck Cancer","enrollment":20},{"nctId":"NCT04418479","phase":"PHASE4","title":"SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3","status":"COMPLETED","sponsor":"Joo-Yong Hahn","startDate":"2020-08-10","conditions":"Coronary Artery Disease","enrollment":5506},{"nctId":"NCT04250116","phase":"PHASE4","title":"Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yonsei University","startDate":"2020-04-28","conditions":"Atrial Fibrillation","enrollment":960},{"nctId":"NCT02209350","phase":"PHASE1","title":"Study of the AFB and Stenting of the Iliac Arteries","status":"COMPLETED","sponsor":"Meshalkin Research Institute of Pathology of Circulation","startDate":"2015-08-02","conditions":"Aorta-iliac Segment Lesion (C,D Type by TASC II)","enrollment":202},{"nctId":"NCT06584812","phase":"PHASE1","title":"Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects","status":"COMPLETED","sponsor":"Tianjin Institute of Pharmaceutical Research Co., Ltd","startDate":"2024-09-09","conditions":"Acute Coronary Syndrome, Ischemic Stroke","enrollment":14},{"nctId":"NCT06588231","phase":"NA","title":"Effect of Individualized Exercise in Elderly Patients With Coronary Heart Disease","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-10-17","conditions":"Coronary Heart Disease","enrollment":200},{"nctId":"NCT04505774","phase":"PHASE4","title":"Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE","status":"COMPLETED","sponsor":"Matthew Neal MD","startDate":"2020-09-04","conditions":"Covid19","enrollment":3591},{"nctId":"NCT03062319","phase":"PHASE4","title":"Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis","status":"TERMINATED","sponsor":"National Hospital Organization Osaka National Hospital","startDate":"2017-04-06","conditions":"Ischemic Stroke, Atrial Fibrillation, Atherothrombosis","enrollment":321},{"nctId":"NCT03606642","phase":"PHASE2","title":"SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy","status":"TERMINATED","sponsor":"HonorHealth Research Institute","startDate":"2018-11-19","conditions":"Coronary Artery Disease, Atherosclerosis, Stent Placement","enrollment":50},{"nctId":"NCT04100135","phase":"NA","title":"GORE® CARDIOFORM Septal Occluder Migraine Clinical Study","status":"TERMINATED","sponsor":"W.L.Gore & Associates","startDate":"2021-02-05","conditions":"Migraine, Patent Foramen Ovale, PFO - Patent Foramen Ovale","enrollment":7},{"nctId":"NCT03729401","phase":"PHASE4","title":"Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND","status":"SUSPENDED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2019-08-22","conditions":"Coronary Artery Disease, Myocardial Infarction","enrollment":390},{"nctId":"NCT05476081","phase":"","title":"A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA","status":"COMPLETED","sponsor":"University of L'Aquila","startDate":"2021-02-03","conditions":"Ischemic Stroke, TIA","enrollment":2239},{"nctId":"NCT05926271","phase":"PHASE2","title":"POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy","status":"RECRUITING","sponsor":"St. Antonius Hospital","startDate":"2023-07-15","conditions":"Acute Coronary Syndrome, CYP2C19 Polymorphism","enrollment":200},{"nctId":"NCT06692933","phase":"EARLY_PHASE1","title":"Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel","status":"RECRUITING","sponsor":"Washington State University","startDate":"2024-06-20","conditions":"Interaction","enrollment":24},{"nctId":"NCT05193071","phase":"PHASE4","title":"Early Antiplatelet for Minor Stroke Following Thrombolysis (EAST)","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2022-07-08","conditions":"Ischemic Stroke","enrollment":1022},{"nctId":"NCT02777580","phase":"PHASE4","title":"STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction","status":"COMPLETED","sponsor":"KU Leuven","startDate":"2017-08-01","conditions":"Myocardial Infarction","enrollment":609},{"nctId":"NCT06577519","phase":"PHASE3","title":"Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","status":"RECRUITING","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2024-09-06","conditions":"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","enrollment":1000},{"nctId":"NCT06613191","phase":"PHASE4","title":"Colonoscopy and Antiplatelet Therapy Trial","status":"NOT_YET_RECRUITING","sponsor":"Ochsner Health System","startDate":"2024-10-01","conditions":"Coronary Arterial Disease (CAD), Peripheral Vascular Disease","enrollment":100},{"nctId":"NCT06591299","phase":"PHASE3","title":"Combining Aspirin With Cilostazol or Clopidogrel in Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-04-15","conditions":"Ischemic Stroke","enrollment":870},{"nctId":"NCT06591351","phase":"PHASE3","title":"Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-05-01","conditions":"Ischemic Stroke","enrollment":870},{"nctId":"NCT06242132","phase":"PHASE3","title":"Clopidogrel Versus Cilostazol in Ischemic Stroke","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2022-06-01","conditions":"Ischemic Stroke","enrollment":870},{"nctId":"NCT06591312","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2022-05-01","conditions":"Ischemic Stroke","enrollment":900}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"_patentsChecked":true,"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":2587,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 10","pmid":"41744521","title":"Overcoming Clopidogrel Resistance in Carotid Artery Stenting: Experience with Ticagrelor and Ticlopidine.","journal":"Clinics and practice"},{"date":"2026 Mar","pmid":"41689871","title":"Mechanism-based inactivation of CYP2C19 by bicuculline and related alteration in pharmacokinetics of clopidogrel.","journal":"Drug metabolism and disposition: the biological fate of chemicals"},{"date":"2026 Jan 5","pmid":"41590858","title":"A Critical Review of the Molecular and Clinical Effects of Cilostazol After Percutaneous Coronary Intervention.","journal":"Journal of cardiovascular development and disease"},{"date":"2025 Dec 17","pmid":"41339124","title":"Carbonylative Ring Expansion of Cyclic Carboxylic Acids.","journal":"Journal of the American Chemical Society"},{"date":"2025 Dec 2","pmid":"41328788","title":"Ticagrelor plus aspirin versus cilostazol plus aspirin in the acute-phase treatment of large-vessel minor stroke or TIA: A randomized controlled multi-center trial, the TACTIS trial.","journal":"International journal of stroke : official journal of the International Stroke Society"}],"companionDiagnostics":[],"genericManufacturers":8,"_genericFilersChecked":true,"genericManufacturerList":["Actavis Elizabeth","Apotex","Chartwell Rx","Mylan","Natco Pharma","Sun Pharm Inds Inc","Teva","Watson Labs"],"phase":"marketed","status":"approved","brandName":"Ticlid","genericName":"TICLOPIDINE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1991","aiSummary":"Ticlid (Ticlopidine) is a small molecule platelet aggregation inhibitor that targets the alpha-2B adrenergic receptor. Originally developed by, it was approved by the FDA in 1991 for indications including cerebrovascular occlusion, percutaneous coronary intervention, prevention of cerebral thrombosis, and subacute stent thrombosis prevention. Ticlid is now off-patent with 8 generic manufacturers. Key safety considerations include potential hematologic and gastrointestinal side effects. As a platelet aggregation inhibitor, Ticlid works by blocking the action of adenosine diphosphate (ADP) on platelets, thereby preventing platelet activation and aggregation.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}